Report Detail
Global Escitalopram Market Insights, Forecast to 2025
- RnM2438872 |
- 05 April, 2019 |
- Global |
- 117 Pages |
- QYResearch |
- Pharma & Healthcare
The global Escitalopram market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Escitalopram market based on company, product type, end user and key regions.
This report studies the global market size of Escitalopram in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Escitalopram in these regions.
This research report categorizes the global Escitalopram market by top players/brands, region, type and end user. This report also studies the global Escitalopram market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Forest Laboratories(US)
H.Lundbeck A/S(DK)
Amneal Pharmaceuticals(US)
Aurobindo Pharma(IN)
Hetero Drugs(IN)
Macleods Pharmaceuticals(IN)
Silarx Pharmacueticals(US)
Apotex(CA)
Hikma Pharmaceuticals(UK)
Jubilant Pharma(SG)
Lupin Limited(IN)
Prinston Pharmaceutical(US)
STI Pharma(US)
TEVA Pharmaceutical(US)
Market size by Product
Solution
Tablet
Others
Market size by End User
Hospitals and Clinics
Individual Use
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Escitalopram market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Escitalopram market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Escitalopram companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Escitalopram submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Escitalopram are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Escitalopram market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Escitalopram Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Escitalopram Market Size Growth Rate by Product
- 1.4.2 Solution
- 1.4.3 Tablet
- 1.4.4 Others
- 1.5 Market by End User
- 1.5.1 Global Escitalopram Market Size Growth Rate by End User
- 1.5.2 Hospitals and Clinics
- 1.5.3 Individual Use
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Escitalopram Market Size
- 2.1.1 Global Escitalopram Revenue 2014-2025
- 2.1.2 Global Escitalopram Sales 2014-2025
- 2.2 Escitalopram Growth Rate by Regions
- 2.2.1 Global Escitalopram Sales by Regions
- 2.2.2 Global Escitalopram Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Escitalopram Sales by Manufacturers
- 3.1.1 Escitalopram Sales by Manufacturers
- 3.1.2 Escitalopram Sales Market Share by Manufacturers
- 3.1.3 Global Escitalopram Market Concentration Ratio (CR5 and HHI)
- 3.2 Escitalopram Revenue by Manufacturers
- 3.2.1 Escitalopram Revenue by Manufacturers (2014-2019)
- 3.2.2 Escitalopram Revenue Share by Manufacturers (2014-2019)
- 3.3 Escitalopram Price by Manufacturers
- 3.4 Escitalopram Manufacturing Base Distribution, Product Types
- 3.4.1 Escitalopram Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Escitalopram Product Type
- 3.4.3 Date of International Manufacturers Enter into Escitalopram Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Escitalopram Sales by Product
- 4.2 Global Escitalopram Revenue by Product
- 4.3 Escitalopram Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Escitalopram Breakdown Data by End User
6 North America
- 6.1 North America Escitalopram by Countries
- 6.1.1 North America Escitalopram Sales by Countries
- 6.1.2 North America Escitalopram Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Escitalopram by Product
- 6.3 North America Escitalopram by End User
7 Europe
- 7.1 Europe Escitalopram by Countries
- 7.1.1 Europe Escitalopram Sales by Countries
- 7.1.2 Europe Escitalopram Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Escitalopram by Product
- 7.3 Europe Escitalopram by End User
8 Asia Pacific
- 8.1 Asia Pacific Escitalopram by Countries
- 8.1.1 Asia Pacific Escitalopram Sales by Countries
- 8.1.2 Asia Pacific Escitalopram Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Escitalopram by Product
- 8.3 Asia Pacific Escitalopram by End User
9 Central & South America
- 9.1 Central & South America Escitalopram by Countries
- 9.1.1 Central & South America Escitalopram Sales by Countries
- 9.1.2 Central & South America Escitalopram Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Escitalopram by Product
- 9.3 Central & South America Escitalopram by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Escitalopram by Countries
- 10.1.1 Middle East and Africa Escitalopram Sales by Countries
- 10.1.2 Middle East and Africa Escitalopram Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Escitalopram by Product
- 10.3 Middle East and Africa Escitalopram by End User
11 Company Profiles
- 11.1 Forest Laboratories(US)
- 11.1.1 Forest Laboratories(US) Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Forest Laboratories(US) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Forest Laboratories(US) Escitalopram Products Offered
- 11.1.5 Forest Laboratories(US) Recent Development
- 11.2 H.Lundbeck A/S(DK)
- 11.2.1 H.Lundbeck A/S(DK) Company Details
- 11.2.2 Company Business Overview
- 11.2.3 H.Lundbeck A/S(DK) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 H.Lundbeck A/S(DK) Escitalopram Products Offered
- 11.2.5 H.Lundbeck A/S(DK) Recent Development
- 11.3 Amneal Pharmaceuticals(US)
- 11.3.1 Amneal Pharmaceuticals(US) Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Amneal Pharmaceuticals(US) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Amneal Pharmaceuticals(US) Escitalopram Products Offered
- 11.3.5 Amneal Pharmaceuticals(US) Recent Development
- 11.4 Aurobindo Pharma(IN)
- 11.4.1 Aurobindo Pharma(IN) Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Aurobindo Pharma(IN) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Aurobindo Pharma(IN) Escitalopram Products Offered
- 11.4.5 Aurobindo Pharma(IN) Recent Development
- 11.5 Hetero Drugs(IN)
- 11.5.1 Hetero Drugs(IN) Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Hetero Drugs(IN) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Hetero Drugs(IN) Escitalopram Products Offered
- 11.5.5 Hetero Drugs(IN) Recent Development
- 11.6 Macleods Pharmaceuticals(IN)
- 11.6.1 Macleods Pharmaceuticals(IN) Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Macleods Pharmaceuticals(IN) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Macleods Pharmaceuticals(IN) Escitalopram Products Offered
- 11.6.5 Macleods Pharmaceuticals(IN) Recent Development
- 11.7 Silarx Pharmacueticals(US)
- 11.7.1 Silarx Pharmacueticals(US) Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Silarx Pharmacueticals(US) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Silarx Pharmacueticals(US) Escitalopram Products Offered
- 11.7.5 Silarx Pharmacueticals(US) Recent Development
- 11.8 Apotex(CA)
- 11.8.1 Apotex(CA) Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Apotex(CA) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Apotex(CA) Escitalopram Products Offered
- 11.8.5 Apotex(CA) Recent Development
- 11.9 Hikma Pharmaceuticals(UK)
- 11.9.1 Hikma Pharmaceuticals(UK) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Hikma Pharmaceuticals(UK) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Hikma Pharmaceuticals(UK) Escitalopram Products Offered
- 11.9.5 Hikma Pharmaceuticals(UK) Recent Development
- 11.10 Jubilant Pharma(SG)
- 11.10.1 Jubilant Pharma(SG) Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Jubilant Pharma(SG) Escitalopram Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Jubilant Pharma(SG) Escitalopram Products Offered
- 11.10.5 Jubilant Pharma(SG) Recent Development
- 11.11 Lupin Limited(IN)
- 11.12 Prinston Pharmaceutical(US)
- 11.13 STI Pharma(US)
- 11.14 TEVA Pharmaceutical(US)
12 Future Forecast
- 12.1 Escitalopram Market Forecast by Regions
- 12.1.1 Global Escitalopram Sales Forecast by Regions 2019-2025
- 12.1.2 Global Escitalopram Revenue Forecast by Regions 2019-2025
- 12.2 Escitalopram Market Forecast by Product
- 12.2.1 Global Escitalopram Sales Forecast by Product 2019-2025
- 12.2.2 Global Escitalopram Revenue Forecast by Product 2019-2025
- 12.3 Escitalopram Market Forecast by End User
- 12.4 North America Escitalopram Forecast
- 12.5 Europe Escitalopram Forecast
- 12.6 Asia Pacific Escitalopram Forecast
- 12.7 Central & South America Escitalopram Forecast
- 12.8 Middle East and Africa Escitalopram Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Escitalopram Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Escitalopram . Industry analysis & Market Report on Escitalopram is a syndicated market report, published as Global Escitalopram Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Escitalopram market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
